Abstract
The drug delivery system described here is based on a virus like particle consisting of the recombinant expressed major capsid protein of Polyomavirus, VP1. Polyoma, a murine virus belonging to the Papovaviridae, forms a non-enveloped icosahedral capsid. These capsids are organized as a double shell composed of three different proteins: VP1,VP2 and VP3. The outer shell of the vision is composed of 360 VP1 molecules arranged as 72 pentamers. These capsids have a diameter of about 50 nm. The VP1 protein acts as a major ligand for certain membrane receptors during virus infection. Furthermore, the N-terminus of the VP1 protein contains a DNA-binding domain and a nuclear localization sequence. The recombinant production of the VP1 protein offers a save way to obtain a highly purified, non-pathogenic pharmaceutical excipient. Combining these aspects, VP1 proteins provide a targeting as well as a drug binding site when used as a save drug carrier for gene therapy. Current applications are also including oligonucleotides as well as small molecules as well as vaccines.
Keywords: artificial virus, virus like particle, vp1 capsids, drug delivery system
Current Pharmaceutical Biotechnology
Title: Recombinant Virus Like Particles as Drug Delivery System
Volume: 6 Issue: 1
Author(s): Christiane Georgens, Jorg Weyermann and Andreas Zimmer
Affiliation:
Keywords: artificial virus, virus like particle, vp1 capsids, drug delivery system
Abstract: The drug delivery system described here is based on a virus like particle consisting of the recombinant expressed major capsid protein of Polyomavirus, VP1. Polyoma, a murine virus belonging to the Papovaviridae, forms a non-enveloped icosahedral capsid. These capsids are organized as a double shell composed of three different proteins: VP1,VP2 and VP3. The outer shell of the vision is composed of 360 VP1 molecules arranged as 72 pentamers. These capsids have a diameter of about 50 nm. The VP1 protein acts as a major ligand for certain membrane receptors during virus infection. Furthermore, the N-terminus of the VP1 protein contains a DNA-binding domain and a nuclear localization sequence. The recombinant production of the VP1 protein offers a save way to obtain a highly purified, non-pathogenic pharmaceutical excipient. Combining these aspects, VP1 proteins provide a targeting as well as a drug binding site when used as a save drug carrier for gene therapy. Current applications are also including oligonucleotides as well as small molecules as well as vaccines.
Export Options
About this article
Cite this article as:
Georgens Christiane, Weyermann Jorg and Zimmer Andreas, Recombinant Virus Like Particles as Drug Delivery System, Current Pharmaceutical Biotechnology 2005; 6 (1) . https://dx.doi.org/10.2174/1389201053167202
DOI https://dx.doi.org/10.2174/1389201053167202 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Posterior Reversible Encephalopathy Syndrome with Atypical Presentation: A Pictorial Review on MR Imaging Features
Current Medical Imaging Carbon Nano-onions: A Valuable Class of Carbon Nanomaterials in Biomedicine
Current Medicinal Chemistry Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action
CNS & Neurological Disorders - Drug Targets Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry Buprenorphine and Buprenorphine/Naloxone Intoxication in Children – How Strong is the Risk?
Current Drug Abuse Reviews Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Aging and DNA Methylation
Current Chemical Biology The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews In Vitro and In Vivo Models of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets